| __timestamp | Geron Corporation | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 16758000 | 10811000 |
| Thursday, January 1, 2015 | 17793000 | 33001000 |
| Friday, January 1, 2016 | 18761000 | 64936000 |
| Sunday, January 1, 2017 | 19287000 | 99909000 |
| Monday, January 1, 2018 | 18707000 | 127724000 |
| Tuesday, January 1, 2019 | 20893000 | 161524000 |
| Wednesday, January 1, 2020 | 25678000 | 182933000 |
| Friday, January 1, 2021 | 29665000 | 219982000 |
| Saturday, January 1, 2022 | 43628000 | 278139000 |
| Sunday, January 1, 2023 | 69135000 | 309799000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. From 2014 to 2023, Ultragenyx Pharmaceutical Inc. and Geron Corporation have taken different paths in optimizing these costs. Ultragenyx's SG&A expenses surged by over 2,700% from 2014 to 2023, reflecting its aggressive growth strategy. In contrast, Geron Corporation's expenses increased by approximately 312% during the same period, indicating a more conservative approach.
Ultragenyx's higher SG&A costs, peaking at $310 million in 2023, suggest significant investment in scaling operations and market expansion. Meanwhile, Geron's expenses, reaching $69 million in 2023, highlight a focus on maintaining lean operations. This divergence in strategy underscores the varied approaches companies take in balancing growth and cost management in the biotech sector.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Ultragenyx Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Geron Corporation
Alkermes plc or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for ACADIA Pharmaceuticals Inc. and Geron Corporation
Who Optimizes SG&A Costs Better? Geron Corporation or Wave Life Sciences Ltd.